Curr Res Transl Med . CAR T-cell Treatment During the COVID-19 Pandemic: Management Strategies and Challenges

[tetano]

Curr Res Transl Med


. 2020 Jun 28;S2452-3186(20)30042-8.
doi: 10.1016/j.retram.2020.06.003. Online ahead of print.
CAR T-cell Treatment During the COVID-19 Pandemic: Management Strategies and Challenges


Yongxian Hu ¹ , Elaine Tan Su Yin ² , Yingying Yang ³ , Hengwei Wu ⁴ , Guoqing Wei ⁵ , Junwei Su ⁶ , Qu Cui ⁷ , Aiyun Jin ⁸ , Li Yang ⁹ , Shan Fu ¹⁰ , Jianfeng Zhou ¹¹ , Lugui Qiu ¹² , Xi Zhang ¹³ , Aibin Liang ¹⁴ , Hongmei Jing ¹⁵ , Yuhua Li ¹⁶ , Didier Blaise ¹⁷ , Mohamad Mohty ¹⁸ , Arnon Nagler ¹⁹ , He Huang ²⁰



Affiliations

• PMID: 32620465
• DOI: 10.1016/j.retram.2020.06.003

Abstract

The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.

Keywords: COVID-19; Chimeric antigen receptor T-cells; Cytokine release syndrome; Immunocompromised; Relapsed/refractory hematological malignancies.